133 related articles for article (PubMed ID: 8020006)
1. Suramin.
Eisenberger MA; Reyno LM
Cancer Treat Rev; 1994 Jul; 20(3):259-73. PubMed ID: 8020006
[No Abstract] [Full Text] [Related]
2. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
3. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
5. Suramin and prostate cancer: where do we go from here?
Clark JW; Chabner BA
J Clin Oncol; 1995 Sep; 13(9):2155-7. PubMed ID: 7666073
[No Abstract] [Full Text] [Related]
6. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
7. [Suramin: pharmacology and antitumor effectiveness of an old parasiticide].
Rebollo J
Med Clin (Barc); 1994 Mar; 102(8):301-5. PubMed ID: 8170229
[No Abstract] [Full Text] [Related]
8. Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Figg WD; Cooper MR; Thibault A; Headlee D; Humphrey J; Bergan RC; Reed E; Sartor O
Cancer; 1994 Sep; 74(5):1612-4. PubMed ID: 8062193
[TBL] [Abstract][Full Text] [Related]
9. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
10. Suramin: the discovery of an old anticancer drug.
Zaniboni A
Med Oncol Tumor Pharmacother; 1990; 7(4):287-90. PubMed ID: 2283894
[TBL] [Abstract][Full Text] [Related]
11. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
12. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
[TBL] [Abstract][Full Text] [Related]
13. Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease.
Van Oosterom AT; De Smedt EA; Denis LJ; de Bruijn EA; Mahler C
Eur J Cancer; 1990 Apr; 26(4):422. PubMed ID: 2141506
[No Abstract] [Full Text] [Related]
14. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
15. Suramin: prototype of a new generation of antitumor compounds.
La Rocca RV; Stein CA; Myers CE
Cancer Cells; 1990 Apr; 2(4):106-15. PubMed ID: 2202382
[TBL] [Abstract][Full Text] [Related]
16. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
[TBL] [Abstract][Full Text] [Related]
18. Suramin: is adaptive control necessary?
Kobayashi K; Vokes EE; Stefansson K; Janisch L; Vogelzang NJ; Berezin F; Ratain MJ
J Clin Oncol; 1992 Dec; 10(12):1984-5; author reply 1985-6. PubMed ID: 1453214
[No Abstract] [Full Text] [Related]
19. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid insufficiency due to suramin therapy.
Kobayashi K; Weiss RE; Vogelzang NJ; Vokes EE; Janisch L; Ratain MJ
Cancer; 1996 Dec; 78(11):2411-20. PubMed ID: 8941013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
